Taltz (ixekizumab) / Eli Lilly, Japan Tobacco - LARVOL DELTA

Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis (EAACI 2025) - "Purpose: We report a patient with severe asthma with nasal polyposis and psoriasis who presented severe atopic dermatitis while he was on treatment with ixekizumab and omalizumab...He started treatment with apremilast with initial remission... Severe psoriasis and severe AD can rarely co-exist in the same patient and the treatment of both conditions can be a therapeutic challenge to the clinician.In these patients dual biological therapy targeting different inflammatory pathways should be considered. Larger studies are needed to further evaluate the efficacy and safety of dual biologic therapy."

Clinical • Atopic Dermatitis • Dermatitis • Immunology • Psoriasis

A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (clinicaltrials.gov) - P3 | N=310 | Recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Treatment of refractory pityriasis rubra pilaris with biologic therapy: a case series. (PubMed, Clin Exp Dermatol) - "Biologics demonstrated variable efficacy: significant responses were seen with secukinumab (n=3/4, 75%), tildrakizumab (n=2/7, 28.6%), ixekizumab (n=1/2, 50%), and risankizumab (n=1/1, 100%). Adalimumab yielded partial response for two patients (n=2/3, 66.7%)...Sequential biologic therapy demonstrated some benefit to non-responders. These findings highlight the need for standardised treatment outcome measures and further research in PRP treatment."

Journal • Dermatology

A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report. (PubMed, Case Rep Dermatol Med) - "Erythrodermic psoriasis (EP) is a severe type of psoriasis that requires immediate and effective treatment to prevent serious complications. Although recommended as first-line treatment for EP, conventional systemic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate and/or cyclosporine can sometimes be ineffective or undesirable, hence the use of biologics. However, in cases of refractory disease, biologics may be combined with methotrexate to boost efficacy and optimize outcomes without compromising safety and tolerability."

Journal • Dermatology • Immunology • Psoriasis

Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey. (PubMed, J Psoriasis Psoriatic Arthritis) - "This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab (GUS) every 8 weeks, and ixekizumab (IXE) every 4 weeks, in managing PsO. No statistically significant differences were observed in dosing frequency preference between treatment groups, suggesting dosing schedule is not a primary concern for most patients. This aligns with previous research demonstrating effective disease control is the most important factor for patient satisfaction; however, tailoring dosing regimens to individual patient needs can also strengthen long-term adherence, as demonstrated in recent studies."

Journal • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Pityriasis rubra pilaris with symmetric polyarthritis and lymphadenopathy. (PubMed, BMJ Case Rep) - "Our patient saw slow improvement in his rash after treatment with ixekizumab and multiple Mohs surgeries for removal of his BCCs with decreased pruritus, erythema and hyperkeratosis. PRP-associated arthritis is a rare component of the primarily dermatologic disorder, and it is important for clinicians to be aware of this association to adequately address joint manifestations."

Journal • Basal Cell Carcinoma • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Non-melanoma Skin Cancer • Pruritus • Rheumatology • Seronegative Spondyloarthropathies • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

IXEKIZUMAB OR INTERLEUKIN-23 INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: KEY REAL-WORLD OUTCOMES FROM THE PROSPECTIVE OBSERVATIONAL PARTUS STUDY IN THE US (EULAR 2025) - "IXE or an IL-23i (guselkumab [GUS] or risankizumab [RZB]) was initiated in accordance with the Food and Drug Administration (FDA) labelling in a US clinical setting. The results from the prospective observational RW study PARTUS showed that patients with active PsA treated with IXE achieved meaningful early improvements by W4 in both disease activity and patient-reported outcomes. Disease outcomes continued to improve up to W12. Patients treated with IXE reached disease activity remission and low disease activity rapidly and through W12."

Clinical • Observational data • Real-world • Real-world evidence • Dermatology • Fatigue • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Oncology • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

SOCIAL MEDIA PERSPECTIVES OF BIOLOGICS AND TARGETED THERAPY IN PSORIATIC ARTHRITIS (EULAR 2025) - "We then narrowed the search to specific treatments using the term ‘psoriatic arthritis’ coupled with ‘adalimumab’, ‘baricitinib’ ‘brodalumab’, ‘certolizumab’, ‘etanercept’, ‘guselkumab’, ‘infliximab’, ‘ixekizumab’, ‘risankizumab’, ‘secukinumab’, ‘tildrakizumab’, ‘tofacitinib’, ‘upadacitinib’, and ‘ustekinumab’ and as well as their respective brand names. Social media perceptions of biologics and targeted therapies are largely positive, however there is significant commentary on downsides including local/systemic adverse effects and lack/loss of efficacy. It is important that physicians in their consultations address these common patient concerns that may be perpetuated by social media."

Immunology • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

ON-LABEL PERSISTENCE THROUGH 24 MONTHS IN PATIENTS WITH PSORIATIC ARTHRITIS USING GUSELKUMAB OR SUBCUTANEOUS INTERLEUKIN-17A INHIBITORS (EULAR 2025) - "Background: A prior study found that patients with psoriatic arthritis (PsA) treated with guselkumab (GUS; a fully human interleukin [IL]-23p19-subunit inhibitor) were ~2x more likely to maintain persistence while following prescribing guidelines at 12 months (M) versus patients treated with subcutaneous (SC) IL-17A inhibitors (IL-17Ai; secukinumab or ixekizumab). This real-world study assessing long-term treatment persistence among patients with active PsA in the US demonstrated that GUS was associated with significantly (1.5x) greater rates of on-label treatment persistence through 24M, compared to SC IL-17Ai."

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

GUSELKUMAB EFFICACY IN PSORIATIC ARTHRITIS: A REAL-WORLD EVIDENCE COMPARISON STUDY WITH ADALIMUMAB AND IL-17A INHIBITORS FROM THE MULTICENTER PROSPECTIVE BIOlogic aPUlian REgistry (BIOPURE) (EULAR 2025) - "In particular, ADA group included pts treated with both originator or biosimilar ADA and in IL-17A-i group treated with secukinumab or ixekizumab...All patients were comparable in terms of inflammation reactants, tender and swollen joint count, mean DAPSA score, corticosteroids use (percentage of patients and prednisone-equivalent daily dose), combination therapy with methotrexate (MTX), and the presence of comorbidities, particularly fibromyalgia, at baseline... In the context of an excellent performance in 24 months of follow-up of all the drugs under study, GUS seems to guarantee a faster response in terms of reaching DAPSA remission, MDA and steroid-sparing at 6 months, regardless of the treatment line."

Clinical • HEOR • Real-world • Real-world evidence • Fibromyalgia • Immunology • Inflammation • Inflammatory Arthritis • Musculoskeletal Pain • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A

REAL-WORLD EXPERIENCE OF IL-17 INHIBITORS IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHROPATHY, INCLUDING DOSE ESCALATION AND INTRA-CLASS DRUG SWITCHING (EULAR 2025) - " Patients commenced on IL-17i (Secukinumab, Ixekizumab and Bimekizumab) for PsA or AxSpA in the rheumatology service at Guys & St Thomas Hospitals NHS Foundation Trust were identified. In our cohort, IL-17i treatments in AxSpA and PSA, showed similar persistence to previous studies of TNF-i therapy, with an average 2-year drug survival of 60%. IL-17i were well-tolerated with 22 patients stopping treatment due to AEs. Dose escalating Secukinumab to 300mg once monthly was equally well-tolerated with only 2 incidences of AEs following dose escalation."

Clinical • Real-world • Real-world evidence • Ankylosing Spondylitis • Atopic Dermatitis • Candidiasis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

SPANISH COHORT OF PSORIATIC ARTHRTIS PATIENTS TREATED WITH GUSELKUMAB (EULAR 2025) - "All 112 patients were previously treated with conventional systemic disease-modifying antirheumatic drugs (csDMARDs), being methotrexate (81.3%), leflunomide (41.1%) and sulfasalazine (19,6%) the most frequent treatments used respectively. A mean of 1.4 csDMARDs and 3.0 bDMARDs and tsDMARDs were used in these patients, being adalimumab (67.9%), etanercept (23.2%), golimumab (24.1%), infliximab (15.2%), certolizumab (20.5%), secukinumab (48.2%), ixekizumab (32.1%) and ustekinumab (19.2%) the most frequent therapeutic agents used. Regarding tsDMARDs JAK-i and apremilast were used in 23.2% and 20.5% of patients respectively (Figure 1B-C-D)... In this study, we present a cohort of patients from the northern of Spain treated with guselkumab under real-world clinical practice conditions with long-term effectiveness data. The drug showed high persistence (84.31% in the first year) in a more complex patient profile than those examined in clinical trials. There were no notable..."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP

Real-World Switching Patterns for Patients with Psoriatic Arthritis on First-Line Advanced Therapies (EULAR 2025) - "Switching was evaluated for the overall population, stratified by the mechanism of action (MOA; reference IL-23i) and individual drugs (reference: risankizumab (RZB))...RZB was associated with significantly lower proportion of switchers (3.8%) than guselkumab (12.9%), followed by secukinumab (18.8%), ixekizumab (20.8%), apremilast (26.9%), etanercept (30.0%) and adalimumab (32.4%) (all P<0.05)... The proportion of PsA patients taking 1LAT who switched over 12 months was the lowest with IL-23i. At the individual drug level, RZB was associated with the lowest odds of switching."

Clinical • Metastases • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Factors for early introduction of bDMARDs in patients with RIC and cancer in remission for less than 5 years. (EULAR 2025) - "Before cancer diagnosis, patients had received TNFi in 69% of cases (etanercept (n= 51), adalimumab (n= 48), infliximab (n= 17), golimumab (n= 10), certolizumab (n= 7)), IL6 in 11,4% of cases (tocilizumab (n= 21), sarilumab (n= 1)), abatacept in 8.3% of cases (n=16), JAKi in 4,7% of cases (n tofacitinib (n= 5), baricitinib (n= 4)), IL17 in 3.6% of cases (secukinumab (n= 5), ixekizumab (n = 2)), rituximab in 2.6% of cases (n=5), and ustekimumab in 0.4% of cases (n=1). After a cancer diagnosis, rituximab and TNFi are the preferred bDMARDs for inflammatory rheumatism (RA, SA, or PsA). The retreatment is more frequent in RA and SA than in PsA and in patients who had less bDMARDs before the cancer. Most patients change therapeutic classes after a cancer diagnosis."

Clinical • Ankylosing Spondylitis • Basal Cell Carcinoma • Gastrointestinal Cancer • Genetic Disorders • Genito-urinary Cancer • Gynecologic Cancers • Immunology • Inflammatory Arthritis • Lung Cancer • Non-melanoma Skin Cancer • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Skin Cancer • Solid Tumor • Spondylarthritis • Urethral Cancer • IL17A • IL6

Myocardial infarction, stroke, venous thromboembolic events, serious infections and malignancy in patients with psoriatic arthritis treated with tofacitinib compared to biologic treatments in the United States (EULAR 2025) - " Pts with PsA aged ≥18 years newly initiating tofacitinib or a biologic (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab [tumour necrosis factor inhibitors (TNFi)]; secukinumab/ixekizumab [interleukin-17 inhibitors (IL-17i)]; risankizumab or ustekinumab) from 15 December 2017–30 September 2022, with ≥12 months of continuous enrolment prior to the index date (date of PsA therapy initiation) were included. In this US claims dataset, there were no significant differences in risk of developing MI/stroke, serious infections or malignancy for tofacitinib vs biologics, among PsA pts not enriched for cardiovascular/VTE risk factors. A decreased risk of VTE with TNFi vs tofacitinib was found, aligning with previous clinical trial data. Limitations included the variable numbers of safety events across treatments and potential uncontrolled confounding of VTE-specific risk factors, such as surgery."

Clinical • Cardiovascular • Dermatology • Dermatopathology • Genetic Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Myocardial Infarction • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Skin Cancer • Solid Tumor • IL17A

Comparative Efficacy of Biologics and Targeted Synthethic Therapies in Patients with Non-Radiographic Axial Spondyloarthritis: A Network Meta-Analysis (EULAR 2025) - "Upadacitinib, etanercept, bimekizumab and infliximab were good (SUCRA 0.6–0.5) and ixekizumab and secukinumab (SUCRA <0.4) were considered effective compared to placebo (Figure 1). In this network meta-analysis, the relative efficacy of biologic and targeted synthetic DMARDs for nr-axSpA showed that certolizumab and golimumab exhibited the highest efficacy for achieving ASAS40 response, with adalimumab and upadacitinib providing strong alternatives. These findings underscore the importance of individualized treatment strategies in the evolving nr-axSpA treatment landscape."

Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis

Comparative persistence and effectiveness of ixekizumab versus other b/tsDMARD classes in real-world PsA treatment: 12-month results from the PRO-SPIRIT study (EULAR 2025) - " The study included data from a total of 1,192 PsA patients who had initiated or switched to a new interleukin-17A (IL-17A) inhibitor (IL-17Ai), specifically either ixekizumab (IXE, N=343) or secukinumab (SEC, either beginning with 150 mg [SEC 150, n=86] or 300 mg [SEC 300, n=78]), IL-12/23i (N=34), IL-23i (N=56), tumor necrosis factor inhibitor (TNFi, N=437), Janus kinase inhibitor (JAKi, N=124), or phosphodiesterase-4 inhibitor (PDE4i, N=32). At 12 months, although comparative persistence was not statistically different between treatment groups, comparative effectiveness analyses revealed that patients were twice as likely to attain cDAPSA REM with IXE than IL-12/23i & IL-23i, with similar improvements for both groups in BSA and MDA. IXE-treated patients also exhibited higher, albeit not statistically different, odds of attaining cDAPSA REM than those receiving SEC TOTAL or a JAKi. Relative to TNFi, IXE-treated patients exhibited significantly greater reductions..."

Clinical • Real-world • Real-world evidence • Immunology • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

ADALIMUMAB vs. IXEKIZUMAB EFFECTIVENESS IN PATIENTS WITH PSORIATIC ARTHRITIS: A REAL-WORLD MULTICENTER STUDY WITH MATCH-ADJUSTED COMPARISONS (EULAR 2025) - "This study is the first RWE, outside of the H2H RCT [1, 2], comparing the effectiveness of ADA and IXE in real-life PsA patients. From the baseline evaluation, both ADA and IXE demonstrated similar improvements in disease activity and functional status, although ADA appeared more effective in achieving DAPSA remission. However, the Italian regulatory rules strongly indicate the use of a biosimilar bDMARD in the first-line treatment, and both treatments showed similar effectiveness in achieving remission if the baseline differences between the treatment groups were considered using match-adjusted comparisons."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

What is the profile of axial spondyloarthritis patients treated with ixekizumab and its effectiveness in clinical practice Results from the ESPADA study (EULAR 2025) - "On the other hand, no statistically significant differences in persistence were observed in the analyzed subgroups: baseline C-reactive protein levels (normal: 52.8%; elevated: 47.0%), HLA-B27 status (negative: 53.9%; positive: 50.1%), number of previous b/tsDMARDs (1: 65.6%; ≥2: 51.8%), previous secukinumab treatment (no: 56.1%; yes: 56.2%). Most axSpA patients treated with IXE in the study cohort had long-standing, highly active disease, involving multiple domains and a history of prior b/tsDMARD treatment. Despite these characteristics, more than half of the patients maintained one-year treatment persistence with IXE, highlighting IXE as a viable therapeutic option. Table 1."

Clinical • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Seronegative Spondyloarthropathies • Spondylarthritis • CRP • IL17A

Efficacy of ixekizumab in radiographic axial spondyloarthritis patients with normal and elevated CRP: A pooled analysis of phase III clinical trials (EULAR 2025) - P3 | "These data indicate that IXE provides substantial benefits in the treatment of patients with r-axSpA with both normal and elevated baseline CRP levels."

P3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Oncology • Seronegative Spondyloarthropathies • Spondylarthritis • CRP • IL17A

Identification of Risk factors for Difficult-to-Treat Ankylosing spondylitis to enhance risk Stratification (EULAR 2025) - "The proposed ASAS consensus definition of D2T -axSpA 1 was utilized: 1) the use of b/tsDMARDs medication from ≥2 therapeutic classes as follows: Anti-TNF (adalimumab, certolizumab pegol, etanercept, infliximab or golimumab), Anti-IL-17 (Secukinumab or Ixekizumab) or Janus-kinase inhibitors (Upadacitinib or Tofacitinib) and 2) elevated CRP post-diagnosis. The study identified distinct clinical features in D2T AS patients, including a higher prevalence of females and smokers, comorbidities such as obesity, dyslipidemia, and depression, and elevated BMI/ CRP levels. Extra-articular manifestations were also more common. HLA-B27 positivity, obesity, and depression were significant risk factors for D2T-axSpA."

Clinical • Ankylosing Spondylitis • CNS Disorders • Crohn's disease • Depression • Dermatology • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Mood Disorders • Obesity • Ocular Inflammation • Psoriasis • Psychiatry • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • Uveitis • CRP • IL17A

Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial (EULAR 2025) - P3 | "At BL, pts were randomised to treatment with IXE Q4W, adalimumab (ADA), or placebo (PBO). In pts with r-axSpA, BL clinical characteristics were similar in the normal and elevated CRP groups with pts experiencing similar disease burden. Across IXE and ADA treatment groups, the elevated CRP group tended to achieve higher treatment responses than the normal CRP group. Whereas in patients with normal CRP, CFB of ASAS individual components, BASDAI and ASDAS improvement was numerically highest in IXE Q4W followed by ADA and PBO."

Clinical • P3 data • Ankylosing Spondylitis • Inflammatory Arthritis • Pain • Seronegative Spondyloarthropathies • Spondylarthritis • CRP

Dissecting Cellulitis of the Scalp Successfully Treated with a Combination of Ixekizumab and Tofacitinib. (PubMed, J Inflamm Res) - "We hope that dermatologists should be aware that early diagnosis of DCS and the application of biologics are essential to quickly control symptoms and prevent from PCA and keloids. This is a patient from the Department of Dermatology, the Second Affiliated Hospital of Zhejiang University School of Medicine."

Journal • Alopecia • Dermatology • Fibrosis • Hidradenitis Suppurativa • Immunology • IL17A

Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple Sclerosis-like syndrome: a systematic review. (PubMed, Rheumatol Int) - No abstract available

Journal • Review • Ankylosing Spondylitis • CNS Disorders • Dermatology • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Multiple Sclerosis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris. (PubMed, Ir J Med Sci) - "The significant reduction in NLR and SII levels in both the IL-17 and IL-23 groups suggests that these markers may be used together rather than separately in treatment follow-up. The significant decrease in PHR levels may indicate that IL-17 and IL-23 inhibitors contribute to reducing cardiovascular disease risk in patients with psoriasis vulgaris and promote a favorable long-term prognosis."

Journal • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Inflammation • Psoriasis • IL17A • IL23A